Bio
Dan joined Connecticut Innovations in 2007 and is responsible for evaluating investment opportunities, structuring new investments and monitoring portfolio companies. Dan serves on the boards of Innovatient Solutions and FMP Products. He has been involved in CI’s investments in and serves as a board observer for Axerion, Affinimark, CyVek, EpiEP, CiDRA, Helix Therapeutics, Metagenomix, Rib-X Pharmaceuticals, LiQuifix and Soft Tissue Regeneration. Dan has also been involved with CI’s investments in Cara Therapeutics and ShopText. Dan also helps to administer Connecticut’s $100 million Stem Cell Research Fund in partnership with the Connecticut Department of Public Health. Dan came to CI with over ten years of experience in the Connecticut biotech arena. He was previously employed by CuraGen Corporation, a successful former CI portfolio company. While at CuraGen, Dan held a variety of scientific and operational management positions. His extensive experience in research and development, technology assessment, and implementation of next generation scientific technologies enabled Dan to help transform CuraGen from a genomic and proteomic platform company into a biopharmaceutical firm dedicated to advancing its protein, antibody and small molecule therapeutics. Dan represents Connecticut Innovations on the board of the Connecticut Venture Group. Dan holds a Bachelor of Science degree in biology from the University of Dayton and earned both Master of Business Administration and Master of Health Sciences degrees from Quinnipiac University.
Career
|
Connecticut Innovations Inc |